NDAORALTABLET
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
ADVIL DUAL ACTION WITH ACETAMINOPHEN (ibuprofen, acetaminophen) by GSK is cyclooxygenase inhibitors [moa]. First approved in 2020.
Drug data last refreshed 3h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADVIL DUAL ACTION WITH ACETAMINOPHEN is an oral tablet combining ibuprofen (NSAID) and acetaminophen for enhanced pain relief. It works via cyclooxygenase inhibition to reduce inflammation and pain. This fixed-dose combination targets patients seeking superior analgesic efficacy over monotherapy options.
Peak15.0 years to LOE
Product is in peak commercial phase with stable market position; brand teams typically maintain established size and focus on optimization rather than expansion.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ADVIL DUAL ACTION offers stable, mature-phase career development in OTC/consumer healthcare with focus on brand management, market share defense, and retail execution. This role suits professionals seeking established product expertise and commercial acumen in the competitive mass-market analgesic space.
Brand Manager
Worked on ADVIL DUAL ACTION WITH ACETAMINOPHEN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.